MetaCap

Mesoblast (MESO) vs Windward Bio Group (WWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Windward Bio Group is the larger company by market cap ($1.45 billion vs $1.41 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MESO-17.94%WWB-14.79%
+7%-8%-22%
Nov 13, 20261 yearNov 20, 2026
MESO-17.94%WWB-14.79%
+1%-9%-19%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MESO versus WWB key metrics
MetricMESOWWB
Share price$10.89$24.29
Market cap$1.41B$1.45B
1-day change-2.59%+1.15%
YTD return-39.63%—
1-year return-29.15%—
5-year return-12.04%—
Forward P/E31.11—
EPS (TTM)$-0.44$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$17.20M—
Revenue growth (YoY)+191.39%—
Net income (latest FY)$-102.14M—
Gross margin70.17%—
Net margin-593.92%—
52-week high$21.50$33.99
52-week low$10.87$18.35
Distance from 52-week high-49.35%-28.55%
Analyst consensusnone—
Avg. price target upside+239.76%—
Average volume240.68K434.33K
Shares outstanding129.85M59.58M
Employees10833
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Mesoblast

MESO stock →

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees

About Windward Bio Group

WWB stock →

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees

MESO vs WWB FAQ

Which is bigger, Mesoblast or Windward Bio Group?

Windward Bio Group (WWB) is larger, with a market capitalization of $1.45B compared with $1.41B for Mesoblast (MESO).

Are Mesoblast and Windward Bio Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons